Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy

Osaki,Rie; Nishimura,Takashi; Takeuchi,Takayuki; Imaeda,Hirotsugu; Okumura,Yoshiaki; Shioya,Makoto; Nakahara,Tamio; Bamba,Shigeki; Nakajo,Shinobu; Fujiyama,Yoshihide; Andoh,Akira

doi:10.3892/etm.2011.250

July-August 2011 Volume 2 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-August 2011 Volume 2 Issue 4

Full Size Image

Article

Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy

Authors:
- Rie Osaki
- Takashi Nishimura
- Takayuki Takeuchi
- Hirotsugu Imaeda
- Yoshiaki Okumura
- Makoto Shioya
- Tamio Nakahara
- Shigeki Bamba
- Shinobu Nakajo
- Yoshihide Fujiyama
- Akira Andoh
View Affiliations / Copyright

Affiliations: Department of Medicine, Graduate School, Shiga University of Medical Science, Seta Tsukinowa, Otsu 520-2192, Japan, Department of Medicine, Notogawa Hospital, Higashioumi, Japan, Department of Medicine, Social Insurance Shiga Hospital, Fujimidai, Otsu, Japan, Division of Mucosal Immunology, Graduate School, Shiga University of Medical Science, Seta Tsukinowa, Otsu 520-2192, Japan
Pages: 715-718
|
Published online on: April 7, 2011

https://doi.org/10.3892/etm.2011.250
Expand metrics +

Abstract

Prediction of the efficacy of pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy against hepatitis C (HCV) infection is valuable for determining its applications. This study investigated the relationship between the early response of HCV to PEG-IFN/RBV therapy and the interleukin (IL)-28B genetic polymorphism in patients with HCV infection. The genotypes of IL-28B rs8099917 T>G single nucleotide polymorphism were determined in 144 patients with HCV infection. Among them, 59 were treated with PEG-IFN/RBV. The frequency of IL-28B TT homozygosity was 75.2% in patients with HCV serotype 1 and 84.6% in patients with serotype 2. Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy. The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection.

View Figures

View References

1.	Alavian SM, Tabatabaei SV, Keshvari M, et al: Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 30:1173–1180. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Welzel TM, Morgan TR, Bonkovsky HL, et al: Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 49:1847–1858. 2009. View Article : Google Scholar
3.	Kurosaki M, Tanaka Y, Nishida N, et al: Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 54:439–448. 2011. View Article : Google Scholar
4.	Yasui K, Harano Y, Mitsuyoshi H, et al: Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol. 45:95–104. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Ochi H, Maekawa T, Abe H, et al: IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol. Jan. 12–2011, (E-pub ahead of print).
6.	Hadziyannis SJ and Koskinas JS: Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res. 29:129–135. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 140:346–355. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Iino S, Ichida F, Sakuma A and Suzuki H: A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks in patients with chronic hepatitis C having genotype 1b infection in high viral titers. Hepatol Res. 24:338–345. 2002. View Article : Google Scholar
9.	Enomoto N, Sakuma I, Asahina Y, et al: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:77–81. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Akuta N, Suzuki F, Kawamura Y, et al: Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 79:1686–1695. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Izumi N, Asahina Y and Kurosaki M: Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat. 2010:7036022010.PubMed/NCBI
12.	Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Ge D, Fellay J, Thompson AJ, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461:399–401. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 14:143–149. 1999.
15.	Marcello T, Grakoui A, Barba-Spaeth G, et al: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 131:1887–1898. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Charlton MR, Pockros PJ and Harrison SA: Impact of obesity on treatment of chronic hepatitis C. Hepatology. 43:1177–1186. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Tsubota A, Fujise K, Namiki Y and Tada N: Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 17:419–432. 2011. View Article : Google Scholar : PubMed/NCBI
18.	McHutchison JG, Lawitz EJ, Shiffman ML, et al: Peginterferon alpha-2b or alpha-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 361:580–593. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles